TUCSON,
Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (NASDAQ: AXDX) announced that management will
host a conference call today, Thursday,
August 8, 2024, at 4:30 p.m. Eastern
Time to review 2024 second quarter results.
To listen to the audio webcast online, visit ir.axdx.com. A
replay of the audio webcast will be available for 30 days.
To listen by phone, dial +1.877.883.0383 and enter the Elite
Entry Number: 9884567. International participants may dial
+1.412.902.6506. Please dial in 10-15 minutes prior to the start of
the conference.
A replay of the call will be available by telephone at
+1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the
replay code 1377013 until August 29, 2024.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company
dedicated to providing solutions for the global challenges of
antibiotic resistance and sepsis. The Accelerate Pheno®
system and Accelerate PhenoTest® BC kit combine several
technologies aimed at reducing the time clinicians must wait to
determine the most optimal antibiotic therapy for deadly
infections. The FDA cleared system and kit fully automate the
sample preparation steps to report phenotypic antibiotic
susceptibility results in approximately 7 hours direct from
positive blood cultures. Recent external studies indicate the
solution offers results 1-2 days faster than existing methods,
enabling clinicians to optimize antibiotic selection and dosage
specific to the individual patient days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENO TEST" and "ACCELERATE WAVE" and diamond shaped
logos and marks are registered trademarks of Accelerate
Diagnostics, Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2024-second-quarter-results-302218055.html
SOURCE Accelerate Diagnostics, Inc.